NICE Delivers Kidney Blow To Cancer Patients With New Guidelines

Once again the National Institute for Health and Clinical Excellence (NICE) has hit the headlines in the UK, after preliminary guidance for kidney cancer treatment found that four expensive new drugs were not cost effective and as such would not be recommended for use. While the drugs - Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), Pfizer's Sutent (sunitinib) and Wyeth's Torisel (temsiromilus) - could extend advanced/metastatic kidney cancer patients' lives by several months, this was deemed at too high a cost for the National Health Service

To read the full article, please choose one of the following options: